Plandaí Biotechnology, Inc. (OTCQB: PLPL) transforming the world of nutraceuticals by making available extracts from live plant material that deliver the highest levels of bioavailability currently in the market. These extracts are utilized to deliver a new family of drugs to safely and cost effectively treats a plethora of different diseases and conditions.
Cognoptix and its technology have the ability to overhaul commonly accepted Alzheimer’s Disease diagnostic practices, providing a tool to diagnose the disease at an early stage, thereby increasing the efficacy of current therapies.
OneMedPlace introduces a new series, “The Briefing Room”, capturing the past week’s most important developments in microcap life sciences indexes. This week, we feature Star Scientific, Kips Bay Medical, XOMA and Stellar Pharmaceuticals.
Valued at almost $6bn in the seven major markets in 2011 (US, Japan, France, Germany, Italy, Spain, and the UK), the Alzheimer’s disease drug market is forecast to experience double-digit growth to 2020.
Over the next 40 years, caring for individuals with Alzheimer’s will cost American society $20 trillion –including $15 trillion to Medicare and Medicaid.
The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.
OR Pharma previously presented at OneMedForum San Francisco and will return in June to preset their technology at OneMedForum NY 2011.
Could the same hormone that regulates your appetite keep you from developing Alzheimer’s?
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
If dementia care were a company, it would be the world’s largest in terms of annual revenue, surpassing even Wal-Mart.
Copyright © 2025 | WordPress Theme by MH Themes